Fungal Infections Diagnosis Market by Type, Diagnostic Method, End-User

Description

List of Tables

[183 Pages Report] The Fungal Infections Diagnosis Market size was estimated at USD 2.09 billion in 2023 and expected to reach USD 2.23 billion in 2024, at a CAGR 6.96% to reach USD 3.35 billion by 2030.

Fungal infections, or mycosis, refer to infections or diseases caused by a fungus species (yeast or mold). Fungal infections are most commonly observed on the skin or nails, but fungi can also cause infections in the mouth, throat, lungs, and urinary tract. Fungal infections come in different forms, such as ringworm athlete's foot, toenail fungus, yeast infections, and jock itch. Diagnosis of fungal infection primarily relies on methodologies such as microscopic examination of clinical samples, histopathology, culture, X-rays, MRI, or CT imaging. The rising incidences of fungal infections across the world have led to a surge in demand for effective disease detection technologies. Furthermore, government initiatives promoting awareness of fungal infection management and efforts to expand access to healthcare facilities have led to rising adoption of fungal infection diagnosis. However, the complexity of molecular and genetic fungal infection diagnosis and the lack of skilled medical and clinical personnel impeded the growth of fungal infection diagnosis solutions. Additionally, inaccurate or inconsistent diagnosis results and stringent regulations pertaining to product approval also pose challenges for fungal infection diagnosis devices, solutions, and services. However, major players are rapidly expanding investments in R&D initiatives to improve the capabilities and accuracy of diagnosis technologies. Advances in imaging technologies enhanced digital solutions for remote diagnosis and the introduction of artificial intelligence in rapid diagnostic techniques present opportunities for growth.

KEY MARKET STATISTICS
Base Year [2023]	USD 2.09 billion
Estimated Year [2024]	USD 2.23 billion
Forecast Year [2030]	USD 3.35 billion
CAGR (%)	6.96%

Regional Insights

The Americas, specifically the US and Canada, present a mature region for fungal infections diagnostic tools, attributable to the increased public consciousness about fungal infections. Americas is characterized by the presence of robust research institutions and medical infrastructure, contributing to the timely and accurate diagnosis of various fungal infections. The technological advancements in diagnostic techniques, including PCR and next-generation sequencing, have accelerated the diagnosis process, improved accuracy, and reduced the potential risk of fatality in the Americas region. In Europe, the spread of fungal infections shows a significant increase, mostly attributed to the elderly population and those with immunosuppressive conditions. There is a rising demand for effective diagnostic tools driven by increased awareness about fungal infections. European region exhibits a rise in travel and migration, which contributes to the introduction and spread of various fungal pathogens. Medical practitioners, therefore, adopt innovative fungal infection diagnostics to manage the potential outbreaks in this high-risk environment effectively. Significant investments in R&D and a growing number of start-ups characterize this region. Asia-Pacific (APAC) region is witnessing an upsurge in the incidence of fungal infections, primarily due to escalating population density and climatic conditions that favor fungal growth. The APAC region, chiefly China, Japan, and India, shows immense potential due to escalating healthcare expenditure and a surge in patient awareness.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Fungal Infections Diagnosis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Prevalence of fungal infections and need for effective diagnosis methods
- Government initiatives promoting awareness of fungal infection management
- Favorable approvals for fungal infection test series

Market Restraints
- Complexity of molecular and genetic fungal infection diagnosis

Market Opportunities
- Advancements in molecular and point-of-care diagnosis technologies
- Potential of teledermatology in fungal infection detection and diagnosis

Market Challenges
- Limitations associated with the inaccuracy of the diagnostic methods

Market Segmentation Analysis
- Type: Growing incidences of opportunistic fungal infections due to weakened immune system in patients
- Diagnostic Method: Advancements in cellular and molecular biology leading to the adoption of molecular diagnostics for infection detection
- End-user: Expanding healthcare expenditure leading to growth and significance of hospitals for fungal infection diagnosis

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Fungal Infections Diagnosis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Fungal Infections Diagnosis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

University of Minnesota Research Team Successfully Tests New Antifungal Therapy For Fungal Meningitis

A research team at the University of Minnesota tested a new antifungal therapy for the treatment of fungal meningitis. The study involves a combination of drugs, which shows promising results in treating fungal infections. This discovery is significant as it could potentially offer new treatment options for individuals affected by fungal infections. The findings of this research offer further advancements in antifungal therapies, providing hope for improved patient outcomes and quality of life. [Published On: 2023-08-22]

Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use

Applied BioCode introduced the Fungal Panel Assay, a cutting-edge diagnostic tool for the accurate identification of fungal infections. Built on their innovative MultiCode-RTx technology, this assay offers reliable detection and precise identification of pathogens. It is designed for research use and can be employed on a variety of biological samples, including blood, saliva, urine, and tissue. With its ability to deliver maximum test capability from minimal input material, the Fungal Panel Assay can help fight against fungal infections. [Published On: 2023-06-12]

University of Arizona Researchers to Help Track Deadly Fungus in Arizona Wastewater

The University of Arizona researchers identified and monitored a dangerous fungal infection known as Candida auris in the wastewater of Arizona. This particular strain of fungus is resistant to drugs and has the potential to cause severe infections, which can be fatal. The researchers have developed precise and accurate tools to track the presence of this fungus, enabling informed decisions regarding public health. Their work contributes to the development of improved policies for the detection and prevention of such hazardous fungal infections. [Published On: 2023-04-11]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Fungal Infections Diagnosis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Fungal Infections Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alexion Pharmaceuticals, Inc., Amgen Inc., Associates of Cape COD, Inc. by Seikagaku Group company, Astellas Pharma Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Bruker Corporation, Danaher Corporation, Eli Lilly and Company, ELITech Group, Eurofins Viracor, LLC, F. Hoffmann-La Roche AG, Hologic, Inc., Immununexpress Inc., IMMY, InBios International, Inc., Laboratory Corporation of America Holdings, Merck KGaA, Norgen Biotek Corp., PerkinElmer, Inc., Polysciences, Inc., Qiagen N.V., Siemens Healthineers, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Fungal Infections Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Endemic Fungal Infections
- Opportunistic Fungal Infections
- Subcutaneous Fungal Infections
- Superficial Fungal Infections
- Systemic Fungal Infections

Diagnostic Method
- Antigen Testing
- Dermatological Examination
- Histopathology
- Microbiological Culture
- Molecular Diagnostics
- Serology

End-User
- Hospitals
- Point-of-Care Settings
- Research Institutions
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-346757DFA1E9

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of fungal infections and need for effective diagnosis methods
  - 5.1.1.2. Government initiatives promoting awareness of fungal infection management
  - 5.1.1.3. Favorable approvals for fungal infection test series
- 5.1.2. Restraints
  - 5.1.2.1. Complexity of molecular and genetic fungal infection diagnosis
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in molecular and point-of-care diagnosis technologies
  - 5.1.3.2. Potential of teledermatology in fungal infection detection and diagnosis
- 5.1.4. Challenges
  - 5.1.4.1. Limitations associated with the inaccuracy of the diagnostic methods
5.2. Market Segmentation Analysis
- 5.2.1. Type: Growing incidences of opportunistic fungal infections due to weakened immune system in patients
- 5.2.2. Diagnostic Method: Advancements in cellular and molecular biology leading to the adoption of molecular diagnostics for infection detection
- 5.2.3. End-user: Expanding healthcare expenditure leading to growth and significance of hospitals for fungal infection diagnosis
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Fungal Infections Diagnosis Market, by Type

6.1. Introduction
6.2. Endemic Fungal Infections
6.3. Opportunistic Fungal Infections
6.4. Subcutaneous Fungal Infections
6.5. Superficial Fungal Infections
6.6. Systemic Fungal Infections

7. Fungal Infections Diagnosis Market, by Diagnostic Method

7.1. Introduction
7.2. Antigen Testing
7.3. Dermatological Examination
7.4. Histopathology
7.5. Microbiological Culture
7.6. Molecular Diagnostics
7.7. Serology

8. Fungal Infections Diagnosis Market, by End-User

8.1. Introduction
8.2. Hospitals
8.3. Point-of-Care Settings
8.4. Research Institutions
8.5. Specialty Clinics

9. Americas Fungal Infections Diagnosis Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Fungal Infections Diagnosis Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Fungal Infections Diagnosis Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. University of Minnesota Research Team Successfully Tests New Antifungal Therapy For Fungal Meningitis
- 12.3.2. Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use
- 12.3.3. University of Arizona Researchers to Help Track Deadly Fungus in Arizona Wastewater
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio